Eterna Therapeutics 13G Filing Shows IAF, LLC Reported A 9.99% Passive Stake In The Co As Of Dec 14
$ERNA
Biotechnology: Pharmaceutical Preparations
Health Care
- SEC Filing
- SEC Filing
Save time and jump to the most important pieces.
CAMBRIDGE, Mass., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) ("Eterna" or the "Company"), a life science company committed to realizing the potential of mRNA cell engineering to provide patients with transformational new medicines, today announced the execution of a securities purchase agreement with accredited investors for the sale of approximately $9.2 million aggregate principal amount of senior convertible promissory notes and accompanying warrants to purchase an aggregate of 9,579,014 shares of common stock in a private placement transaction that was priced at-the-market under Nasdaq rules. The Company expects to hold an initial closing at which it exp
CAMBRIDGE, MASS., July 18, 2023 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (NASDAQ:ERNA) ("Eterna" or the "Company"), a life science company committed to realizing the potential of mRNA cell engineering to provide patients with transformational new medicines, today announced the execution and closing of the sale of approximately $8.7 million aggregate principal amount of senior convertible promissory notes and accompanying warrants to purchase common stock in a private placement transaction that closed on July 14, 2023 and was priced at-the-market under Nasdaq rules. The notes, which were issued at par, bear interest at a rate of 6.0% per year, payable quarterly, and mature in July 2028
Acquisition includes Exacis' entire pipeline of engineered cell therapy programs for hematologic and solid tumors CAMBRIDGE, Mass., May 02, 2023 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (NASDAQ:ERNA) ("Eterna" or the "Company"), a life science company committed to realizing the potential of mRNA cell engineering to provide patients with transformational new medicines, today announced the acquisition of the global immuno-oncology platform of Exacis Biotherapeutics ("Exacis"). The acquisition complements Eterna's core business with a pipeline of allogeneic immuno-oncology products under development for the treatment of hematologic and solid tumors and provides Eterna with an exclusive g
CAMBRIDGE, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (NASDAQ:ERNA) ("Eterna" or the "Company") announced today that it has regained compliance with Nasdaq for continued listing and that its stock will continue to trade on The Nasdaq Stock Market. Eterna received formal confirmation on November 12th, 2024 from Nasdaq's Office of General Counsel, verifying that Eterna has met the market value of listed securities standard of at least $35 million, outlined in Listing Rule 5550(b)(2), and that Eterna is in compliance with all applicable continued listing standards. "With this achievement and the recent updates we've announced, we have transformed our company into a deb
CAMBRIDGE, Mass., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (NASDAQ:ERNA) ("Eterna" or the "Company") today announced the successful completion of a comprehensive financial restructuring of the Company with the aim to accelerate its developmental activities and long-term success. This restructuring includes reduction of its liabilities by discontinuing a longstanding lease, reducing the debt on its balance sheet and a new round of financing through a private investment in public equity (PIPE) investment. As a part of this financial restructuring, the Company has significantly reduced its liability by discontinuing a longstanding lease, resulting in an estimated $72 millio
The presentation reports the development of a beta 2 microglobulin-knockout (B2M-KO) iMSC line with enhanced immunosuppressive activity and stealthing features that may further augment the therapeutic potential of MSCs in treating inflammatory diseases by precluding batch-to-batch inconsistencies, promoting in vivo persistence, and enhancing the effector function of the cellsThe presentation is on Saturday, May 11th, 2024 CAMBRIDGE, Mass., May 10, 2024 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (NASDAQ:ERNA) ("Eterna" or the "Company"), a biopharmaceutical company using advanced cell engineering technology to develop transformational new medicines, today announces that Raven Hinkel wi
4 - Eterna Therapeutics Inc. (0000748592) (Issuer)
4 - Eterna Therapeutics Inc. (0000748592) (Issuer)
4 - Eterna Therapeutics Inc. (0000748592) (Issuer)
424B3 - Eterna Therapeutics Inc. (0000748592) (Filer)
424B3 - Eterna Therapeutics Inc. (0000748592) (Filer)
424B3 - Eterna Therapeutics Inc. (0000748592) (Filer)
CAMBRIDGE, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (NASDAQ:ERNA) ("Eterna" or the "Company"), a preclinical-stage biopharmaceutical company, committed to realizing the potential of mRNA cell engineering to provide patients with transformational new medicines, today announces the appointment of Mahendra Rao, PhD, to its scientific advisory board. "We're honored to have Dr. Mahendra Rao join our Scientific Advisory Board," said Sanjeev Luther, President and CEO of Eterna. "His deep scientific expertise in regenerative medicine and cell engineering will be invaluable to our company in its upcoming phases of scientific and clinical development as we strive to brin
CAMBRIDGE, Mass., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (NASDAQ:ERNA) ("Eterna" or the "Company"), a life science company committed to realizing the potential of mRNA cell engineering to provide patients with transformational new medicines, today announced the appointment of Peter Cicala, JD, to its Board of Directors. "Peter Cicala has deep experience in the biotechnology and pharmaceutical industry, from start-ups to big pharma, and from bench to commercialization," said Sanjeev Luther, President and CEO of Eterna. "We are very pleased to have him join our Board to support value creation through the development of next-generation therapies using mRNA cell engineerin
CAMBRIDGE, Mass., Dec. 20, 2023 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (NASDAQ:ERNA) ("Eterna" or the "Company"), a life science company committed to realizing the potential of mRNA cell engineering to provide patients with transformational new medicines, has appointed Sanjeev Luther as President and Chief Executive Officer and a member of the company's Board of Directors, effective January 1, 2024. Mr. Luther will replace Matt Angel, Ph.D., the current President and Chief Executive Officer. James Bristol, Ph.D., Chairman of Eterna's Board of Directors, said, "We are excited to have Sanjeev take on the role of President and CEO of Eterna as we continue our work to support the deve
4 - Eterna Therapeutics Inc. (0000748592) (Issuer)
Gainers Structure Therapeutics (NASDAQ:GPCR) stock moved upwards by 71.0% to $58.47 during Monday's regular session. The market value of their outstanding shares is at $2.7 billion. Concord Medical Services (NYSE:CCM) stock rose 55.96% to $0.78. The company's market cap stands at $33.8 million. Microbot Medical (NASDAQ:MBOT) shares moved upwards by 40.79% to $1.41. The market value of their outstanding shares is at $20.2 million. Bio-Path Hldgs (NASDAQ:BPTH) shares moved upwards by 38.0% to $2.84. The market value of their outstanding shares is at $4.7 million. Olema Pharmaceuticals (NASDAQ:OLMA) shares rose 23.45% to $11.95. The market value of their outstanding shares is at $668.4 mil
The presentation reports the development of a beta 2 microglobulin-knockout (B2M-KO) iMSC line with enhanced immunosuppressive activity and stealthing features that may further augment the therapeutic potential of MSCs in treating inflammatory diseases by precluding batch-to-batch inconsistencies, promoting in vivo persistence, and enhancing the effector function of the cellsThe presentation is on Saturday, May 11th, 2024CAMBRIDGE, Mass., May 10, 2024 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (NASDAQ:ERNA) ("Eterna" or the "Company"), a biopharmaceutical company using advanced cell engineering technology to develop transformational new medicines, today announces that Raven Hinkel will pre
The presentation reports the development of a beta 2 microglobulin-knockout (B2M-KO) iMSC line with enhanced immunosuppressive activity and stealthing features that may further augment the therapeutic potential of MSCs in treating inflammatory diseases by precluding batch-to-batch inconsistencies, promoting in vivo persistence, and enhancing the effector function of the cells The presentation is on Saturday, May 11th, 2024CAMBRIDGE, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (NASDAQ:ERNA) ("Eterna" or the "Company"), a biopharmaceutical company using advanced cell engineering technology to develop transformational new medicines, today announces that Raven Hinkel will p